Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H20N2O2S |
| Molecular Weight | 316.418 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)C1=C(N)SC2=C1CCN(CC3=CC=CC=C3)C2
InChI
InChIKey=PFENFDGYVLAFBR-UHFFFAOYSA-N
InChI=1S/C17H20N2O2S/c1-2-21-17(20)15-13-8-9-19(11-14(13)22-16(15)18)10-12-6-4-3-5-7-12/h3-7H,2,8-11,18H2,1H3
| Molecular Formula | C17H20N2O2S |
| Molecular Weight | 316.418 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.obatapasaja.com/2015/05/komposisi-dosis-dan-harga-nonflamin.html
http://www.ncbi.nlm.nih.gov/pubmed/702946
Curator's Comment: description was created based on several sources, including:
http://www.obatapasaja.com/2015/05/komposisi-dosis-dan-harga-nonflamin.html
http://www.ncbi.nlm.nih.gov/pubmed/702946
Tinoridine is a non-steroidal anti-inflammatory and analgesic agent. This agent has been proved pharmacologically to show antiedematous and analgesic actions. The mechanism of the anti-inflammatory action of Tinoridine is attributed to its biomembrane stabilizing action particularly on the lysosomes which are related to cell or tissue damage at the time of inflammation through the release of hydrolytic enzymes. Tinoridine may produce gastrointestinal disorders (nausea, loss of appetite, diarrhea, and constipation), vertigo drowsiness, dry mouth and itching.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | Nonflamin Approved UseTinoridine is indicated as anti-inflammatory agent after surgery injuries or injury in urology. |
|||
| Primary | Nonflamin Approved UseTinoridine is used to treat pharyngitis, laryngitis, tonsillitis. |
|||
| Primary | Nonflamin Approved UseFor analgesic purpose, Tinoridine is used to treat back pain. |
|||
| Primary | Nonflamin Approved UseFor analgesic purpose, Tinoridine is used to treat lumbago. |
|||
| Primary | Nonflamin Approved UseTinoridine is indicated to treat pain in chronic rheumatic diseases. |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
8.2 h CLINICAL TRIAL https://europepmc.org/article/med/6605310 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
TINORIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
8.2 h CLINICAL TRIAL https://europepmc.org/article/med/6605310 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
TINORIDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Disc. AE: Nausea, Appetite lost... AEs leading to discontinuation/dose reduction: Nausea Sources: Appetite lost Diarrhoea Constipation Vertigo Drowsiness Dry mouth Itching |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Appetite lost | Disc. AE | 100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Constipation | Disc. AE | 100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Diarrhoea | Disc. AE | 100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Drowsiness | Disc. AE | 100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Dry mouth | Disc. AE | 100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Itching | Disc. AE | 100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Nausea | Disc. AE | 100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Vertigo | Disc. AE | 100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Sample Use Guides
In Vitro Use Guide
Curator's Comment: Tinoridine, at concentrations from 5 microM up to 100 microM, produced a concentration-dependent inhibition on the simultaneous increases in lipid peroxide formation and renin release induced by 50 microM ascorbic acid in the renin granule fraction.
http://www.ncbi.nlm.nih.gov/pubmed/3906080
30 uM of Tinoridine HCl hydrochloride inhibited the Phospholipase C-induced lysosomal enzyme release from rat liver lysosomes.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:07:49 GMT 2025
by
admin
on
Mon Mar 31 18:07:49 GMT 2025
|
| Record UNII |
C9Z9ICZ7YR
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Mon Mar 31 18:07:49 GMT 2025 , Edited by admin on Mon Mar 31 18:07:49 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
m1263
Created by
admin on Mon Mar 31 18:07:49 GMT 2025 , Edited by admin on Mon Mar 31 18:07:49 GMT 2025
|
PRIMARY | Merck Index | ||
|
SUB11077MIG
Created by
admin on Mon Mar 31 18:07:49 GMT 2025 , Edited by admin on Mon Mar 31 18:07:49 GMT 2025
|
PRIMARY | |||
|
100000077227
Created by
admin on Mon Mar 31 18:07:49 GMT 2025 , Edited by admin on Mon Mar 31 18:07:49 GMT 2025
|
PRIMARY | |||
|
2672
Created by
admin on Mon Mar 31 18:07:49 GMT 2025 , Edited by admin on Mon Mar 31 18:07:49 GMT 2025
|
PRIMARY | |||
|
158555
Created by
admin on Mon Mar 31 18:07:49 GMT 2025 , Edited by admin on Mon Mar 31 18:07:49 GMT 2025
|
PRIMARY | |||
|
C9Z9ICZ7YR
Created by
admin on Mon Mar 31 18:07:49 GMT 2025 , Edited by admin on Mon Mar 31 18:07:49 GMT 2025
|
PRIMARY | |||
|
C76821
Created by
admin on Mon Mar 31 18:07:49 GMT 2025 , Edited by admin on Mon Mar 31 18:07:49 GMT 2025
|
PRIMARY | |||
|
24237-54-5
Created by
admin on Mon Mar 31 18:07:49 GMT 2025 , Edited by admin on Mon Mar 31 18:07:49 GMT 2025
|
PRIMARY | |||
|
3079
Created by
admin on Mon Mar 31 18:07:49 GMT 2025 , Edited by admin on Mon Mar 31 18:07:49 GMT 2025
|
PRIMARY | |||
|
CHEMBL592943
Created by
admin on Mon Mar 31 18:07:49 GMT 2025 , Edited by admin on Mon Mar 31 18:07:49 GMT 2025
|
PRIMARY | |||
|
DB13001
Created by
admin on Mon Mar 31 18:07:49 GMT 2025 , Edited by admin on Mon Mar 31 18:07:49 GMT 2025
|
PRIMARY | |||
|
C100290
Created by
admin on Mon Mar 31 18:07:49 GMT 2025 , Edited by admin on Mon Mar 31 18:07:49 GMT 2025
|
PRIMARY | |||
|
5480
Created by
admin on Mon Mar 31 18:07:49 GMT 2025 , Edited by admin on Mon Mar 31 18:07:49 GMT 2025
|
PRIMARY | |||
|
246-102-0
Created by
admin on Mon Mar 31 18:07:49 GMT 2025 , Edited by admin on Mon Mar 31 18:07:49 GMT 2025
|
PRIMARY | |||
|
DTXSID9023677
Created by
admin on Mon Mar 31 18:07:49 GMT 2025 , Edited by admin on Mon Mar 31 18:07:49 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
